Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease

Brain Research Bulletin

Volumn 82, Issue 1-2, 2010, Pages 29-38

  Ambrosi, G ^a   Armentero, M T ^a   Levandis, G ^a   Bramanti, P ^b   Nappi, G ^a,c   Blandini, F ^a  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^b IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

6 Hydroxydopamine; Astroglia; Behaviour; Microglia; MPEP

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; NEUROTOXIN; OXIDOPAMINE;

AKINESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BASAL GANGLION; CELL ACTIVATION; CELL SURVIVAL; CONTROLLED STUDY; DISEASE MODEL; ENCEPHALITIS; MALE; MICROGLIA; MOTOR DYSFUNCTION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; STRIATONIGRAL DEGENERATION;

ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; INFLAMMATION; MALE; MOTOR ACTIVITY; NEURONS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PYRIDINES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; SUBSTANTIA NIGRA;

EID: 77952319804     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2010.01.011     Document Type: Article

References (61)

1. Aguirre J.A., Kehr J., Yoshitake T., Liu F.L., Rivera A., Fernandez-Espinola S., Andbjer B., Leo G., Medhurst A.D., Agnati L.F., Fuxe K. Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP. Brain Res. 2005, 1033:216-220.
2. Alam M., Danysz W., Schmidt W.J., Dekundy A. Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats. Toxicol. Appl. Pharmacol. 2009, 198-207.
3. Armentero M.T., Fancellu R., Nappi G., Bramanti P., Blandini F. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease. Neurobiol. Dis. 2006, 22:1-9.
4. Armentero M.T., Levandis G., Nappi G., Bazzini E., Blandini F. Peripheral inflammation and neuroprotection: systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease. Neurobiol. Dis. 2006, 24:492-505.
5. Bartels A.L., Leenders K.L. Neuroinflammation in the pathophysiology of Parkinson's disease: evidence from animal models to human in vivo studies with [11C]-PK11195 PET. Mov. Disord. 2007, 22:1852-1856.
6. Benarroch E.E. Subthalamic nucleus and its connections: anatomic substrate for the network effects of deep brain stimulation. Neurology 2008, 70:1991-1995.
7. Blandini F., Armentero M.T., Fancellu R., Blaugrund E., Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp. Neurol. 2004, 187:455-459.
8. Blandini F., Levandis G., Bazzini E., Nappi G., Armentero M.T. Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model. Eur. J. Neurosci. 2007, 25:397-405.
9. Block M.L., Hong J.S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 2005, 76:77-98.
10. Breysse N., Baunez C., Spooren W., Gasparini F., Amalric M. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J. Neurosci. 2002, 22:5669-5678.
11. Breysse N., Amalric M., Salin P. Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats. J. Neurosci. 2003, 23:8302-8309.
12. Byrnes K.R., Stoica B., Loane D.J., Riccio A., Davis M.I., Faden A.I. Metabotropic glutamate receptor 5 activation inhibits microglial associated inflammation and neurotoxicity. Glia 2009, 57:550-560.
13. Chen L., Zhang Q., Liu J., Wang S., Ali U., Gui Z., Wang Y. Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist in 6-hydroxydopamine partially lesioned rats reverses abnormal firing of dopaminergic neurons. Brain Res. 2009, 1286:192-200.
14. Choi D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988, 1:623-634.
15. Colburn R.W., DeLeo J.A., Rickman A.J., Yeager M.P., Kwon P., Hickey W.F. Dissociation of microglial activation and neuropathic pain behaviors following peripheral nerve injury in the rat. J. Neuroimmunol. 1997, 79:163-175.
16. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 1997, 37:205-237.
17. Corti C., Battaglia G., Molinaro G., Riozzi B., Pittaluga A., Corsi M., Mugnaini M., Nicoletti F., Bruno V. The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection. J. Neurosci. 2007, 27:8297-8308.
18. D'Antoni S., Berretta A., Bonaccorso C.M., Bruno V., Aronica E., Nicoletti F., Catania M.V. Metabotropic glutamate receptors in glial cells. Neurochem. Res. 2008, 33:2436-2443.
19. Darlington C. Astrocytes as targets for neuroprotective drugs. Curr. Opin. Investig. Drugs 2005, 6:700-703.
20. Davalos D., Grutzendler J., Yang G., Kim J.V., Zuo Y., Jung S., Littman D.R., Dustin M.L., Gan W.B. ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 2005, 8:752-758.
21. Edling Y., Ingelman-Sundberg M., Simi A. Glutamate activates c-fos in glial cells via a novel mechanism involving the glutamate receptor subtype mGlu5 and the transcriptional repressor DREAM. Glia 2007, 55:328-340.
22. Ferraguti F., Corti C., Valerio E., Mion S., Xuereb J. Activated astrocytes in areas of kainate-induced neuronal injury upregulate the expression of the metabotropic glutamate receptors 2/3 and 5. Exp. Brain Res. 2001, 137:1-11.
23. Gao X., Hu X., Qian L., Yang S., Zhang W., Zhang D., Wu X., Frase rA., Wilson B., Flood P., Block M., Hong J. Formyl-methionyl-leucyl-phenylalanine-induced dopaminergic neurotoxicity via microglial activation: a mediator between peripheral infection and neurodegeneration?. Environ. Health Perspect. 2008, 116:593-598.
24. Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., Eggert K., Oertel W., Banati R.B., Brooks D.J. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 2006, 21:404-412.
25. Golembiowska K., Konieczny J., Ossowska K., Wolfarth S. The role of striatal metabotropic glutamate receptors in degeneration of dopamine neurons: review article. Amino Acids 2002, 23:199-205.
26. Greenamyre J.T. Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J. Neural Transm. Gen. Sect. 1993, 91:255-269.
27. Greenamyre J.T., Hastings T.G. Biomedicine. Parkinson's-divergent causes, convergent mechanisms. Science 2004, 304:1120-1122.
28. Hald A., Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?. Exp. Neurol. 2005, 193:279-290.
29. Henry V., Paillé V., Lelan F., Brachet P., Damier P. Kinetics of microglial activation and degeneration of dopamine-containing neurons in a rat model of Parkinson disease induced by 6-hydroxydopamine. Neuropathol. Exp. Neurol. 2009, 62:1092-1102.
30. Hilker R., Portman A.T., Voges J., Staal M.J., Burghaus L., van Laar T., Koulousakis A., Maguire R.P., Pruim J., de Jong B.M., Herholz K., Sturm V., Heiss W.D., Leenders K.L. Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation. J. Neurol. Neurosurg. Psychiatry 2005, 76:1217-1221.
31. Hirsch E.C., Hoglinger G., Rousselet E., Breidert T., Parain K., Feger J., Ruberg M., Prigent A., Cohen-Salmon C., Launay J.M. Animal models of Parkinson's disease in rodents induced by toxins: an update. J. Neural. Transm. Suppl. 2003, 89-100.
32. Kanumilli S., Roberts P.J. Mechanisms of glutamate receptor induced proliferation of astrocytes. Neuroreport 2006, 17:1877-1881.
33. Kirik D., Rosenblad C., Bjorklund A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur. J. Neurosci. 2000, 11:3871-3882.
34. Kress G.J., Reynolds I.J. Dopaminergic neurotoxins require excitotoxic stimulation in organotypic cultures. Neurobiol. Dis. 2005, 20:639-645.
35. Lange K.W., Kornhuber J., Riederer P. Dopamine/glutamate interactions in Parkinson's disease. Neurosci. Biobehav. Rev. 1997, 21:393-400.
36. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 1999, 46:598-605.
37. Levandis G., Bazzini E., Armentero M.T., Nappi G., Blandini F. Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neurobiol. Dis. 2008, 29:161-168.
38. Liu B. Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease. AAPS J. 2006, 8:E606-E621.
39. Loane D.J., Stoica B.A., Pajoohesh-Ganji A., Byrnes K.R., Faden A.I. Activation of metabotropic glutamate receptor 5 modulates microglial reactivity and neurotoxicity by inhibiting NADPH oxidase. J. Biol. Chem. 2009, 284:15629-15639.
40. Marinova-Mutafchieva L., Sadeghian M., Broom L., Davis J.B., Medhurst A.D., Dexter D.T. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease. J. Neurochem. 2009, 110:966-975.
41. Movsesyan V.A., O'Leary D.M., Fan L., Bao W., Mullins P.G., Knoblach S.M., Faden A.I. mGluR5 antagonists 2-methyl-6-(phenylethynyl)-pyridine and (E)-2-methyl-6-(2-phenylethenyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-methyl-d-aspartate receptors. J. Pharmacol. Exp. Ther. 2001, 296:41-47.
42. Mudo G., Trovato-Salinaro A., Caniglia G., Cheng Q., Condorelli D.F. Cellular localization of mGluR3 and mGluR5 mRNAs in normal and injured rat brain. Brain Res. 2007, 1149:1-13.
43. Nakahara K., Okada M., Nakanishi S. The metabotropic glutamate receptor mGluR5 induces calcium oscillations in cultured astrocytes via protein kinase C phosphorylation. J. Neurochem. 1997, 69:1467-1475.
44. Nicholls D.G., Ward M.W. Mitochondrial membrane potential and neuronal glutamate excitotoxicity: mortality and millivolts. Trends Neurosci. 2000, 23:166-174.
45. Nimmerjahn A., Kirchhoff F., Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308:1314-1318.
46. Olsson M., Nikkhah G., Bentlage C., Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J. Neurosci. 1995, 15:3863-3875.
47. Ossowska K., Konieczny J., Wolfarth S., Wieronska J., Pilc A. Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology 2001, 41:413-420.
48. Paxinos, Watson The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, San Diego. fourth edition.
49. Phillips J.M., Lam H.A., Ackerson L.C., Maidment N.T. Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease. Eur. J. Neurosci. 2006, 23:151-160.
50. Purisai M.G., McCormack A.L., Cumine S., Li J., Isla M.Z., Di Monte D.A. Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol. Dis. 2007, 25:392-400.
51. Romano C., van den Pol A.N., O'Malley K.L. Enhanced early developmental expression of the metabotropic glutamate receptor mGluR5 in rat brain: protein, mRNA splice variants, and regional distribution. J. Comp. Neurol. 1996, 367:403-412.
52. Temel Y., Visser-Vandewalle V., Kaplan S., Kozan R., Daemen M.A., Blokland A., Schmitz C., Steinbusch H.W. Protection of nigral cell death by bilateral subthalamic nucleus stimulation. Brain Res. 2006, 1120:100-105.
53. Tilleux S., Berger J., Hermans E. Induction of astrogliosis by activated microglia is associated with a down-regulation of metabotropic glutamate receptor 5. J. Neuroimmunol. 2007, 189:23-30.
54. Ulas J., Satou T., Ivins K.J., Kesslak J.P., Cotman C.W., Balazs R. Expression of metabotropic glutamate receptor 5 is increased in astrocytes after kainate-induced epileptic seizures. Glia 2000, 30:352-361.
55. Vernon A.C., Palmer S., Datla K.P., Zbarsky V., Croucher M.J., Dexter D.T. Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease. Eur. J. Neurosci. 2005, 22:1799-1806.
56. Vernon A.C., Zbarsky V., Datla K.P., Croucher M.J., Dexter D.T. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo. J. Neurochem. 2007, 103:1075-1091.
57. Vernon A.C., Croucher M.J., Dexter D.T. Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson's model. Neuroreport 2008, 19:475-478.
58. Zhou M., Baudry M. Developmental changes in NMDA neurotoxicity reflect developmental changes in subunit composition of NMDA receptors. J. Neurosci. 2006, 26:2956-2963.
59. Zhou Y., Wang Y., Kovacs M., Jin J., Zhang J. Microglial activation induced by neurodegeneration: a proteomic analysis. Mol. Cell Proteomics 2005, 4:1471-1479.
60. Zhu A., Wang X., Yu M., Wang J.Q., Brownell A.L. Evaluation of four pyridine analogs to characterize 6-OHDA-induced modulation of mGluR5 function in rat brain using microPET studies. J. Cereb. Blood Flow Metab. 2007, 27:1623-1631.
61. Zipp F., Aktas O. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci. 2006, 29:518-527.